Linagliptin for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2759-2762

  Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

DPP IV inhibitor; Linagliptin; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; LINAGLIPTIN; PLACEBO;

ARTICLE; BACKACHE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 81255150186     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.613825     Document Type: Article

References (11)

1. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258-67
2. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study ofVascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):S14-21
3. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971 - 1993. Diabetes Care 1998;21:1138-45
4. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010;38:667-78
5. Boehringer Ingelheim Pharmaceuticals, Inc. Tradjenta™ (linagliptin) prescribing information. Ridgefield, CT. 2011. Available from: http://bidocs.boehringeringelheim. com/BIWebAccess/ViewServlet. ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/ Tradjenta.pdf [Last accessed 19 May 2011]
6. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;CD006739
7. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010;30:463-84
8. Graefe-Mody EU, Padula S, Ring A, et al. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009;25:1963-72
9. Friedrich C, Emser A, Woerle HJ, Graefe-Mody EU. Renal impairment has no relevant effect on long-term exposure of linagliptin in patients with type 2 diabetes mellitus. Presented at the 71st Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, 24 - 28 June 2011
10. Pozzilli P, Leslie RD, Chan J, et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010;26:239-44
11. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-9